ES2052745T3 - Formulaciones farmaceuticas que contienen melfalan o hidrocloruro de melfalan, asi como melfalan e hidrocloruro de melfalan y procedimientos para prepararlas. - Google Patents

Formulaciones farmaceuticas que contienen melfalan o hidrocloruro de melfalan, asi como melfalan e hidrocloruro de melfalan y procedimientos para prepararlas.

Info

Publication number
ES2052745T3
ES2052745T3 ES88310805T ES88310805T ES2052745T3 ES 2052745 T3 ES2052745 T3 ES 2052745T3 ES 88310805 T ES88310805 T ES 88310805T ES 88310805 T ES88310805 T ES 88310805T ES 2052745 T3 ES2052745 T3 ES 2052745T3
Authority
ES
Spain
Prior art keywords
melfalan
hydrochloride
well
pharmaceutical formulations
formulations containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88310805T
Other languages
English (en)
Inventor
Stephen William Poole
Timothy Paul Stanley
Geoffrey Divall
Terence William Packham
Joseph Knight
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Application granted granted Critical
Publication of ES2052745T3 publication Critical patent/ES2052745T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UNA FORMULACION FARMACEUTICA DE DOS COMPONENTES NUEVA DE MELFALANO EN LA QUE LOS DOS COMPONENTES COMPRENDEN A) HIDROCLORURO DE MELFALANO, SECADO POR CONGELACION Y B) UN DILUYENTE - SOLVENTE QUE COMPRENDE UN CITRATO, PROPILENGLICOL Y ETANOL. MELFALANO FUNDAMENTALMENTE PURO, HIDROCLORURO DE MELFALANO FUNDAMENTALMENTE PURO Y METODOS PARA PREPARARLOS SE DESCRIBEN TAMBIEN.
ES88310805T 1987-11-19 1988-11-16 Formulaciones farmaceuticas que contienen melfalan o hidrocloruro de melfalan, asi como melfalan e hidrocloruro de melfalan y procedimientos para prepararlas. Expired - Lifetime ES2052745T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB878727157A GB8727157D0 (en) 1987-11-19 1987-11-19 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
ES2052745T3 true ES2052745T3 (es) 1994-07-16

Family

ID=10627252

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88310805T Expired - Lifetime ES2052745T3 (es) 1987-11-19 1988-11-16 Formulaciones farmaceuticas que contienen melfalan o hidrocloruro de melfalan, asi como melfalan e hidrocloruro de melfalan y procedimientos para prepararlas.

Country Status (22)

Country Link
US (1) US4997651A (es)
EP (1) EP0317281B1 (es)
JP (1) JP2693191B2 (es)
KR (1) KR970002607B1 (es)
AT (1) ATE83922T1 (es)
AU (1) AU619781B2 (es)
CA (1) CA1341114C (es)
DE (1) DE3877151T2 (es)
DK (1) DK172794B1 (es)
ES (1) ES2052745T3 (es)
FI (2) FI90204C (es)
GB (1) GB8727157D0 (es)
GR (1) GR3007287T3 (es)
HK (1) HK108994A (es)
HU (3) HU206671B (es)
IE (1) IE63996B1 (es)
IL (1) IL88419A (es)
LV (1) LV10179B (es)
NZ (2) NZ227004A (es)
PT (1) PT89028B (es)
SG (1) SG73894G (es)
ZA (1) ZA888674B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5407672A (en) * 1993-04-08 1995-04-18 Cornell Research Foundation, Inc. Enhancing the anti-tumor effect of melphalan with L-amino acid oxidase
US5695751A (en) * 1993-04-08 1997-12-09 Cornell Research Foundation, Inc. Enhancing delivery of large neutral amino acid drugs
US6020004A (en) * 1997-04-17 2000-02-01 Amgen Inc. Biodegradable microparticles for the sustained delivery of therapeutic drugs
US5980904A (en) * 1998-11-18 1999-11-09 Amway Corporation Skin whitening composition containing bearberry extract and a reducing agent
GB2386066A (en) * 2002-02-28 2003-09-10 Norbrook Lab Ltd Long-acting parasiticidal composition with improved bioavailability comprising a salicylanilide, a further anti-parasitic compound & a polymeric species
EP1523318A4 (en) * 2002-06-24 2007-07-04 Res Dev Foundation TREATMENT OF HUMAN MULTIPLE MYELOMA BY CURCUMIN
EP1694335A4 (en) 2003-08-26 2008-12-31 Res Dev Foundation OSTEOCLASTOGENESIS HEMMER AND ITS USES
US8501818B2 (en) 2005-03-14 2013-08-06 Ceptaris Therapeutics, Inc. Stabilized compositions of alkylating agents and methods of using same
US7872050B2 (en) 2005-03-14 2011-01-18 Yaupon Therapeutics Inc. Stabilized compositions of volatile alkylating agents and methods of using thereof
LT2273876T (lt) 2008-03-27 2019-05-27 Helsinn Healthcare Sa Stabilizuotos alkilinimo medžiagų kompozicijos ir jų panaudojimo būdai
AR066943A1 (es) * 2008-06-10 2009-09-23 Eriochem Sa Una composicion farmaceutica de melfalano
MX357677B (es) 2009-05-29 2018-07-19 Cydex Pharmaceuticals Inc Composiciones inyectables de melfalán que comprenden un derivado de ciclodextrina y métodos de fabricación y uso de las mismas.
US11020363B2 (en) 2009-05-29 2021-06-01 Cydex Pharmaceuticals, Inc. Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
AR077384A1 (es) 2010-07-05 2011-08-24 Eriochem Sa Una formulacion farmaceutica inyectable de melfalano.
US8921596B2 (en) * 2010-11-04 2014-12-30 Emcure Pharmaceuticals, Ltd. Process for the preparation of melphalan hydrochloride
PT3656393T (pt) 2011-04-28 2022-11-03 Oncopeptides Ab Preparação liofilizada de dipéptidos citotóxicos
CA2889753C (en) * 2012-10-26 2021-03-02 Oncopeptides Ab Lyophilized preparations of melphalan flufenamide
WO2014141294A2 (en) 2013-03-11 2014-09-18 Biophore India Pharmaceuticals Pvt. Ltd. An improved process for the synthesis of melphalan and the hydrochloride salt
ITMI20130896A1 (it) * 2013-05-31 2014-12-01 Farmabios Spa Processo di purificazione di melphalan
US10576101B2 (en) * 2015-03-06 2020-03-03 Leadiant Biosciences Sa Roneparstat combined therapy of multiple myeloma
US10537520B2 (en) * 2015-06-30 2020-01-21 Leiutis Pharmaceuticals Pvt. Ltd. Stable liquid formulations of melphalan
KR20200136997A (ko) * 2018-03-29 2020-12-08 프로젝트 파마슈틱스 게엠베하 액체 약학적 제형
US10682326B1 (en) 2019-06-03 2020-06-16 Shilpa Medicare Limited Stable melphalan liquid injectable formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB750155A (en) * 1953-03-17 1956-06-13 Nat Res Dev Substituted alanines
US3032585A (en) * 1954-12-03 1962-05-01 Nat Res Dev Process for the production of p-bis-(2-chloroethyl)-aminophenylalanine
DE1292660B (de) * 1963-04-24 1969-04-17 Ural Polytechnitscheskij I Im Verfahren zur Herstellung von p-(Bis-ª‰-chloraethyl-amino)-phenylalanin-hydrochlorid
US4029778A (en) * 1969-01-23 1977-06-14 Aktiebolaget Leo Cortical steroid nitrogen mustard compositions and treatment therewith
RO57195A2 (es) * 1970-11-30 1974-09-01
FR2285855A1 (fr) * 1974-09-25 1976-04-23 Kohjin Co Composition therapeutique lyophilisee a base de sel de cyclocytidine et son procede de preparation
JPS59186924A (ja) * 1983-04-08 1984-10-23 Kureha Chem Ind Co Ltd ヒト免疫グロブリン結合抗腫瘍剤
US4696814A (en) * 1985-08-21 1987-09-29 Warner-Lambert Company Parenteral phenytoin compositions
JPS62192357A (ja) * 1986-02-19 1987-08-22 Kureha Chem Ind Co Ltd Ｎ−フタロイル−ｐ−ニトロ−Ｌ−フエニルアラニンの製造方法

Also Published As

Publication number Publication date
AU2574888A (en) 1989-05-25
DK172794B1 (da) 1999-07-19
PT89028B (pt) 1993-02-26
DE3877151D1 (de) 1993-02-11
FI924668A (fi) 1992-10-15
HU207286B (en) 1993-03-29
HUT48198A (en) 1989-05-29
FI924668A0 (fi) 1992-10-15
FI102275B1 (fi) 1998-11-13
EP0317281B1 (en) 1992-12-30
LV10179B (en) 1995-06-20
DK646688A (da) 1989-05-20
JP2693191B2 (ja) 1997-12-24
HU910336D0 (en) 1991-08-28
KR970002607B1 (ko) 1997-03-06
FI90204C (fi) 1994-01-10
IE63996B1 (en) 1995-06-28
HK108994A (en) 1994-10-14
EP0317281A2 (en) 1989-05-24
DK646688D0 (da) 1988-11-18
US4997651A (en) 1991-03-05
ZA888674B (en) 1990-07-25
FI90204B (fi) 1993-09-30
KR890007729A (ko) 1989-07-05
IE883447L (en) 1989-05-19
EP0317281A3 (en) 1989-08-09
HU206671B (en) 1992-12-28
HU203197B (en) 1991-06-28
ATE83922T1 (de) 1993-01-15
CA1341114C (en) 2000-10-10
HU9100335D0 (en) 1991-08-28
SG73894G (en) 1994-11-25
IL88419A (en) 1993-03-15
FI102275B (fi) 1998-11-13
LV10179A (lv) 1994-10-20
JPH01153628A (ja) 1989-06-15
IL88419A0 (en) 1989-06-30
GR3007287T3 (es) 1993-07-30
FI885358A (fi) 1989-05-20
PT89028A (pt) 1988-12-01
NZ227004A (en) 1992-11-25
DE3877151T2 (de) 1993-07-15
NZ239867A (en) 1992-11-25
FI885358A0 (fi) 1988-11-18
GB8727157D0 (en) 1987-12-23
AU619781B2 (en) 1992-02-06

Similar Documents

Publication Publication Date Title
ES2052745T3 (es) Formulaciones farmaceuticas que contienen melfalan o hidrocloruro de melfalan, asi como melfalan e hidrocloruro de melfalan y procedimientos para prepararlas.
ES2037682T3 (es) Procedimiento para la preparacion de composiciones farmaceuticas empleando quitosanos metilados.
ES499363A0 (es) Procedimiento para la obtencion de derivados de fenilpipera-cina de 1,3,4-oxadiazolilfenoles
DK430380A (da) Fremgangsmaade til fremstilling af piperidinderivater af 4,5-dialkyl-3-hydroxypyrrol-2-carboxylsyreestere
ES2040774T3 (es) Procedimiento para la preparacion de una formulacion medicamentosa.
SE8503447D0 (sv) Farmaceutiska och kosmetiska kompositioner, innehallande dihydroxi-1,8-fenyl-10-antron-9 som verksam bestandsdel, samt sett att framstella den verksamma foreningen
EP0030688A3 (en) Piperidine derivatives of 3-hydroxy-thiophene-2-carboxylic acid esters, their preparation, and pharmaceutical preparations containing them
MY105860A (en) Pharmaceutical formulations.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 317281

Country of ref document: ES